HB 227 would substantially expand Texas regulation of kratom products and add kratom and kratom alkaloids to the Texas Controlled Substances Act. The bill redesignates the existing kratom chapter, tightens definitions, and requires kratom products to be tested by an in-state ISO-accredited laboratory for alkaloid content, heavy metals, pesticides, microbial contamination, and other substances set by rule. It also requires labeling with safe-use directions and serving sizes, and makes it an offense to sell kratom products that are not properly tested or labeled.
The bill creates or expands a series of criminal prohibitions involving kratom, including sales of adulterated or contaminated products, products with synthetic or artificial alkaloids, products with excessive 7-hydroxymitragynine, kratom beverages, and most prepackaged foods containing kratom. It also prohibits sales to people under 21, sales within 1,000 feet of a school, false laboratory reports, sales of kratom at locations that also sell hemp, tobacco, e-cigarettes, or alcohol, and manufacture or sale of kratom products for smoking or in pill/tablet form. Most of these offenses are Class A misdemeanors, while falsifying lab results is a third-degree felony.
In addition to the kratom-specific chapter, the bill amends the Texas Controlled Substances Act to define kratom and place kratom alkaloids, synthetic equivalents, and related analogues into Penalty Group 1. It also adds tianeptine-related language and makes corresponding updates to controlled-substance definitions and penalty-group listings. The bill increases civil penalties for violations of the kratom chapter from $250/$500/$1,000 to $2,500/$5,000/$10,000 for first, second, and subsequent violations, and authorizes enforcement actions by the attorney general and local prosecutors.
Because there were no committee transcripts or recorded votes provided, there is no documented debate or voting pattern to gauge support or opposition. Based on the bill text alone, the measure appears aimed at restricting and standardizing kratom commerce through stronger testing, labeling, age, location, and product-form limits, while also treating certain kratom compounds as controlled substances. The likely point of contention is the bill’s broad criminalization of kratom products and its move to classify kratom alkaloids and analogues alongside controlled substances, which would affect retailers, processors, laboratories, and consumers.
HB 227 would amend the Health and Safety Code by renumbering and revising the state’s kratom product chapter and by adding kratom-related substances to the Texas Controlled Substances Act. It would impose new testing, labeling, sales, and product-content requirements on kratom processors and retailers, create multiple new criminal offenses, raise civil penalties, and authorize enforcement by state and local prosecutors. It would also expand controlled-substance definitions to include kratom alkaloids, synthetic equivalents, and related analogues, affecting manufacturers, distributors, retailers, laboratories, and consumers of kratom products.
No committee discussion or vote history was provided, so there is no recorded public sentiment from hearings or floor action. From the bill text, the policy direction is clearly restrictive and enforcement-focused, suggesting support from lawmakers concerned about product safety, youth access, and synthetic or adulterated kratom products. At the same time, the breadth of the prohibitions and the controlled-substance treatment of kratom compounds would likely draw concern from kratom businesses, consumer advocates, and others who view the plant as a lawful or less harmful alternative product.
The main points of contention are likely to be the bill’s classification of kratom alkaloids and analogues as controlled substances, the increase in criminal penalties, and the broad bans on certain product forms and retail settings. Retailers and processors may object to the prohibition on sales near schools, to minors under 21, in stores that also sell hemp, tobacco, e-cigarettes, or alcohol, and on kratom in beverages, pills, or tablets. Public health supporters may favor the testing, labeling, and contamination rules, while opponents may argue that the bill overreaches by criminalizing a wide range of kratom commerce and treating kratom more like an illicit drug than a regulated consumer product.